ID   SF7761
AC   CVCL_IT45
DR   Cosmic; 1925952
DR   GEO; GSM1508943
DR   GEO; GSM1508944
DR   GEO; GSM1508945
DR   GEO; GSM1508946
DR   GEO; GSM1508947
DR   GEO; GSM1508948
DR   GEO; GSM1508951
DR   GEO; GSM4969604
DR   GEO; GSM4969605
DR   GEO; GSM4969606
DR   GEO; GSM4969607
DR   GEO; GSM4969620
DR   GEO; GSM4969649
DR   GEO; GSM4969650
DR   GEO; GSM4969651
DR   GEO; GSM5356023
DR   GEO; GSM5434618
DR   GEO; GSM5434619
DR   GEO; GSM5434620
DR   GEO; GSM5434621
DR   GEO; GSM5434622
DR   GEO; GSM5434623
DR   GEO; GSM5434624
DR   GEO; GSM5434625
DR   GEO; GSM5434626
DR   GEO; GSM5434627
DR   GEO; GSM5434628
DR   GEO; GSM5434629
DR   Millipore; SCC126
DR   Wikidata; Q54952936
RX   PubMed=22983601;
RX   PubMed=23603901;
RX   PubMed=25401693;
RX   PubMed=25939062;
RX   PubMed=26115193;
RX   PubMed=32229503;
RX   PubMed=34078608;
RX   PubMed=34732238;
CC   Doubling time: 48 hours (PubMed=22983601).
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=23603901; PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Glu540Ter (c.1618G>T); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; CNV analysis.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): Millipore=SCC126; PubMed=34732238
ST   Amelogenin: X
ST   CSF1PO: 12 (PubMed=34732238)
ST   CSF1PO: 13 (Millipore=SCC126)
ST   D13S317: 8,9
ST   D16S539: 11
ST   D18S51: 19,22
ST   D21S11: 28,31.2
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 11,15
ST   FGA: 20
ST   Penta D: 13
ST   Penta E: 14,17
ST   TH01: 7,9.3
ST   TPOX: 11,12
ST   vWA: 14,18
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Telomerase immortalized cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 15
//
RX   PubMed=22983601; DOI=10.1007/s11060-012-0973-6;
RA   Hashizume R., Smirnov I., Liu S., Phillips J.J., Hyer J.D.,
RA   McKnight T.R., Wendland M., Prados M.D., Banerjee A., Nicolaides T.,
RA   Mueller S., James C.D., Gupta N.;
RT   "Characterization of a diffuse intrinsic pontine glioma cell line:
RT   implications for future investigations and treatment.";
RL   J. Neurooncol. 110:305-313(2012).
//
RX   PubMed=23603901; DOI=10.1101/gad.217778.113; PMCID=PMC3656328;
RA   Chan K.-M., Fang D., Gan H.-Y., Hashizume R., Yu C.-H., Schroeder M.,
RA   Gupta N., Mueller S., James C.D., Jenkins R.B., Sarkaria J.,
RA   Zhang Z.-G.;
RT   "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27
RT   methylation and gene expression.";
RL   Genes Dev. 27:985-990(2013).
//
RX   PubMed=25401693; DOI=10.1038/nm.3716; PMCID=PMC4257862;
RA   Hashizume R., Andor N., Ihara Y., Lerner R., Gan H.-Y., Chen X.-Y.,
RA   Fang D., Huang X., Tom M.W., Ngo V., Solomon D.A., Mueller S.,
RA   Paris P.L., Zhang Z.-G., Petritsch C.K., Gupta N., Waldman T.A.,
RA   James C.D.;
RT   "Pharmacologic inhibition of histone demethylation as a therapy for
RT   pediatric brainstem glioma.";
RL   Nat. Med. 20:1394-1396(2014).
//
RX   PubMed=25939062; DOI=10.1038/nm.3855; PMCID=PMC4862411;
RA   Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N.,
RA   Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J.,
RA   Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C.,
RA   Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L.,
RA   Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J.,
RA   Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J.,
RA   Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N.,
RA   Keller C., Pal R., Grill J., Monje M.;
RT   "Functionally defined therapeutic targets in diffuse intrinsic pontine
RT   glioma.";
RL   Nat. Med. 21:555-559(2015).
//
RX   PubMed=26115193; DOI=10.1097/NEN.0000000000000216; PMCID=PMC4596247;
RA   Taylor I.C., Hutt-Cabezas M., Brandt W.D., Kambhampati M.,
RA   Nazarian J., Chang H.T., Warren K.E., Eberhart C.G., Raabe E.H.;
RT   "Disrupting NOTCH slows diffuse intrinsic pontine glioma growth,
RT   enhances radiation sensitivity, and shows combinatorial efficacy with
RT   bromodomain inhibition.";
RL   J. Neuropathol. Exp. Neurol. 74:778-790(2015).
//
RX   PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507;
RA   Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H.,
RA   Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S.,
RA   Yan H.;
RT   "Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma
RT   cells to the PARP inhibitor olaparib.";
RL   Mol. Cancer Res. 18:968-980(2020).
//
RX   PubMed=34078608; DOI=10.1126/sciadv.abg4126; PMCID=PMC10166578;
RA   Wang J., Huang T.Y.-T., Hou Y., Bartom E.T., Lu X.-Y., Shilatifard A.,
RA   Yue F., Saratsis A.M.;
RT   "Epigenomic landscape and 3D genome structure in pediatric high-grade
RT   glioma.";
RL   Sci. Adv. 7:eabg4126.1-eabg4126.16(2021).
//
RX   PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061;
RA   Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H.,
RA   Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.;
RT   "TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are
RT   sensitive to a MDM2 antagonist.";
RL   Acta Neuropathol. Commun. 9:178.1-178.12(2021).
//